Core Viewpoint - The company, Jiaying Pharmaceutical, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact its operations and reputation [1]. Group 1: Company Overview - Jiaying Pharmaceutical specializes in the research, production, and sales of traditional Chinese medicine, holding a significant position in the industry with 58 drug varieties across 5 dosage forms [3]. - The company's leading products, Shuangliao Houfeng San and Zhonggan Ling Pian, have been recognized as national protected traditional Chinese medicine varieties and have won the "Guangdong Province Famous Brand Product" title [3]. - Jiaying Pharmaceutical's subsidiary, Jiaying Hunan, produces unique products listed in the national medical insurance directory, including Jieguzhi Qili Pian and Jieguzhi Qili Jiao Nang, both of which have patent authorization [3]. Group 2: Financial Performance - In 2024, Jiaying Pharmaceutical reported total revenue of 376 million yuan, a year-on-year decline of 29.46%, and a net profit attributable to shareholders of 20.61 million yuan, down 39.94% [3]. - Despite the financial challenges, the company has implemented measures such as optimizing production processes and enhancing cost control to maintain stable core business operations [3]. - In Q1 2025, Jiaying Pharmaceutical achieved revenue of 122 million yuan, a year-on-year increase of 28.83%, primarily due to expanded sales channels [3]. - The net profit attributable to shareholders for the same period was 15.40 million yuan, reflecting a significant year-on-year growth of 197.23%, driven by successful partnerships with major retail chains and improved cost management [3]. Group 3: Corporate Governance - During a recent earnings briefing, the company addressed investor concerns regarding its governance, stating that the current Secretary of the Board was recruited from a state-owned enterprise, emphasizing high compliance management standards [4]. - The company has undertaken substantial efforts in compliance and internal control, including appointing dedicated compliance personnel and implementing electronic process management [4]. - Future plans include enhancing compliance systems and culture, ensuring business operations and information disclosures are compliant and scientifically managed [4].

Group 1 - Jia Ying Pharmaceutical is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, having received a notice of case filing on May 28, 2025 [2] - ST United plans to acquire 100% of Run Tian Industrial through a combination of share issuance and cash payment, with the stock set to resume trading on May 29 [3] - Long Gao Co., Ltd. is undergoing a restructuring of its controlling shareholder, Longyan Investment Development Group, which has established a new investment development group with a registered capital of 3 billion yuan [4] Group 2 - San You Chemical's controlling shareholder intends to inject 100 million yuan into its subsidiary, Tangshan San You Silicon Industry, through a private agreement [5] - ST Ji Pharmaceutical's stock will be delisted on May 29, 2025, due to a continuous closing price below 1 yuan for twenty trading days [6] - Hehe Information plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy and brand recognition [8] Group 3 - ST Huaxi has signed a significant contract worth approximately 2.9 billion USD (about 20.84 billion yuan) for a project in Iraq, which represents 80.38% of its latest audited revenue [9] - ST Longjin's stock will enter a delisting preparation period starting June 6, 2025, following a decision by the Shenzhen Stock Exchange [10] - Zhenbao Island's wholly-owned subsidiary intends to acquire a 49% stake in its controlling subsidiary, Guizhou Shennong Valley [11]

Group 1 - Jia Ying Pharmaceutical is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, having received a notice of case filing on May 28, 2025 [2] - ST United plans to acquire 100% of Run Tian Industrial through a combination of share issuance and cash payment, aiming to enhance its positioning as a comprehensive service provider in cultural tourism consumption [3] - Long Gao Co., Ltd. announced the restructuring of its controlling shareholder, Longyan Investment Development Group, which has established a new investment development group with a registered capital of 3 billion yuan [4] Group 2 - Sanyou Chemical's controlling shareholder intends to inject 100 million yuan into its subsidiary, Tangshan Sanyou Silicon Industry Co., Ltd., through a private agreement, without affecting the consolidation scope of the company [5] - ST Ji Pharmaceutical's stock will be delisted on May 29, 2025, due to a continuous closing price below 1 yuan for twenty trading days, triggering termination of listing rules [6] - Taiji Industrial plans to repurchase shares worth 100 million to 120 million yuan, with a maximum repurchase price of 10.38 yuan per share [7] Group 3 - China Energy Construction's subsidiary has won a bid for a coal power project worth approximately 14.586 billion yuan, marking a significant contract win [8][9]

关于收到中国证券监督管理委员会立案告知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）于 2025 年 5 月 28 日收到中 国证券监督管理委员会（以下简称"中国证监会"）的《立案告知书》（证监立案 字 0062025010 号），因公司涉嫌信息披露违法违规，根据《中华人民共和国证券 法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 证券代码：002198 证券简称：嘉应制药 公告编号：2025-033 广东嘉应制药股份有限公司 公司将积极配合中国证监会的相关工作，并严格按照规定及监管要求履行信 息披露义务。公司指定的信息披露媒体为《证券时报》《中国证券报》《证券日报》 和巨潮资讯网（http://www.cninfo.com.cn），公司相关信息均以在上述指定信息披 露媒体登载的公告为准。敬请广大投资者关注公司相关公告，理性投资，注意投 资风险。 特此公告。 广东嘉应制药股份有限公司董事会 2025 年 5 月 29 日 ...

Group 1 - Zhongjin Gold plans to inject four companies, including Inner Mongolia Jintao, into the company to resolve competition issues, acquiring stakes of 49.34%, 80%, 70%, and 70% respectively [3] - Keli Yuan intends to invest an additional 500 million yuan in a storage industry fund, increasing its total commitment from 200 million yuan to 700 million yuan, holding 49.93% of the fund [4] - China Shenhua plans to acquire a 7.43% stake in the National Energy Group Financial Company for 2.929 billion yuan, which is expected to increase its net profit by 97 million yuan [5] Group 2 - Weier Co. plans to issue H-shares and list on the Hong Kong Stock Exchange, considering the interests of existing shareholders [6] - China Communication Signal plans to invest approximately 3.789 billion yuan in 11 major rail transit projects, accounting for 11.67% of its audited revenue for 2024 [8] - Intercontinental Oil and Gas intends to invest approximately 848 million USD in the Iraq South Basra Integrated Project, with a total investment of about 1.266 billion USD [9] Group 3 - Jiaying Pharmaceutical's subsidiary signed a technology development contract with Hunan University of Chinese Medicine to develop a new traditional Chinese medicine [10] - Ruide Intelligent signed a strategic cooperation agreement with Shunde Vocational and Technical College to enhance collaboration in technology and talent development [11] - Jiaojian Co. and its partners won a bid for a drainage project worth 225 million yuan, with an expected contribution of 101 million yuan to the company's revenue [12] Group 4 - Hengshun Vinegar's controlling shareholder plans to increase its stake in the company by investing between 50 million and 100 million yuan [14] - Changhua Group's shareholder platform intends to reduce its stake by up to 3%, amounting to a maximum of 14.1 million shares [15] Group 5 - Yunzhongma plans to raise no more than 640 million yuan through a private placement to fund projects for producing DTY yarn and high-performance leather base fabric [17]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： ? 本次签署的《技术开发合同》确立了双方的合作关系，具体实施进度和 最终成果尚存在不确定性，敬请广大投资者谨慎决策，注意投资风险。 证券代码：002198 证券简称：嘉应制药 公告编号：2025-032 广东嘉应制药股份有限公司 ? 本次技术开发合同的签署不会对公司及子公司 2025 年度财务状况及经 营业绩构成重大影响，对公司未来年度经营业绩的影响将视双方后续项目的实施 进展情况确定。 一、协议签署概况 近日，广东嘉应制药股份有限公司（以下简称"公司"）全资子公司嘉应制药 （湖南）有限公司（以下简称"子公司"或"乙方"）与湖南中医药大学（以下简称 "甲方"）签署《技术开发合同》。 根据《深圳证券交易所股票上市规则》《公司章程》等相关规定，本次合同 的签署不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重 大资产重组，无需提交股东会和董事会审议。 二、合同签署概况 单位名称：湖南中医药大学 法定代表人：易刚强 注册资本：198,931 万元 注册地址：长沙市岳麓区含浦科教产业园学士路 3 ...

证券代码：002198 证券简称：嘉应制药 公告编号：2025-032 广东嘉应制药股份有限公司 关于子公司签署《技术开发合同》的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 近日，广东嘉应制药股份有限公司（以下简称"公司"）全资子公司嘉应制药 （湖南）有限公司（以下简称"子公司"或"乙方"）与湖南中医药大学（以下简称 "甲方"）签署《技术开发合同》。 根据《深圳证券交易所股票上市规则》《公司章程》等相关规定，本次合同 的签署不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重 大资产重组，无需提交股东会和董事会审议。 二、合同签署概况 单位名称：湖南中医药大学 法定代表人：易刚强 注册资本：198,931 万元 注册地址：长沙市岳麓区含浦科教产业园学士路 300 号 宗旨和业务范围：培养高等学历医药人才，促进卫生事业发展。 中医药学 科大专、本科、研究生、硕士研究生、博士研究生学历教育、博士后培养相关科 学研究、继续教育、专业培训、学术交流相关社会服务。 本次签署的《技术开发合同》确立了双方的合作关系，具体实施进 ...

广东嘉应制药股份有限公司 证券代码：002198 证券简称：嘉应制药 公告编号：2025-031 截至本公告披露日，史俊平先生未持有公司股票，公司及公司董事会对史俊 平先生任职财务总监期间为公司发展所做的贡献表示衷心感谢！公司将按照相关 规定尽快完成财务总监的选聘工作，并及时履行信息披露义务。 特此公告。 广东嘉应制药股份有限公司董事会 2025 年 5 月 20 日 关于公司财务总监辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）董事会于近日收到公司财务 总监史俊平先生提交的书面辞职报告。史俊平先生因个人原因辞去公司财务总监 职务，根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作》《公司章程》等相关规定，其辞职报 告自送达董事会之日起生效，辞任后不再担任公司任何职务，也不会影响公司的 正常运行。 ...

（一）会议召开情况 2024 年度股东大会决议公告 证券代码：002198 证券简称：嘉应制药 公告编号：2025-030 广东嘉应制药股份有限公司 2024 年度股东大会决议公告 本公司及全体董事、监事、高级管理人员保证公告内容真实、准确和完整， 公告不存在虚假记载、误导性陈述或者重大遗漏。 特别提示： 本次股东大会未出现否决议案的情况，也不存在涉及变更前次股东大会决议的 情形。 一、会议召开和出席情况 2、现场会议召开地点：广东省梅州市东升工业园B区广东嘉应制药股份有限公 司会议室。 3、会议表决方式：采用现场表决与网络投票相结合的方式。 4、会议召集人：公司董事会。 5、会议主持人：董事长李能。 6、本次股东大会召集、召开程序符合《公司法》《上市公司股东大会规则》 等法律、法规、规范性文件和《公司章程》的规定。 1 2024 年度股东大会决议公告 1、会议召开的时间： （1）现场会议：2025年5月16日（星期五）下午14：30； （2）网络投票：2025年5月16日。 通过深交所交易系统进行网络投票的具体时间为2025年5月16日上午9:15至 9:25，9：30至11：30，下午13：00至15：0 ...

湖南启元律师事务所 关于广东嘉应制药股份有限公司 2024年年度股东大会的 法律意见书 致：广东嘉应制药股份有限公司 湖南启元律师事务所（以下简称"本所"）接受广东嘉应制药股份有限公司 （以下简称"公司"）的委托，指派律师出席了公司 2024 年年度股东大会（以下 简称"本次股东大会"），对本次股东大会的召集和召开程序、出席会议人员及 召集人的资格、表决程序和表决结果的合法有效性进行律师见证，并发表本法律 意见。 本所根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）等我国现行法律、法规、规范 性文件以及《广东嘉应制药股份有限公司章程》（以下简称"《公司章程》"） 的有关规定出具本法律意见书。 为出具本法律意见书，本所声明如下： （一）本所出具本法律意见书是基于公司已承诺所有提供给本所的文件的正 本以及经本所查验与正本保持一致的副本均为真实、完整、可靠，无隐瞒、虚假 或重大遗漏之处。 （二）本所遵循了勤勉尽责和诚实信用原则，严格履行了法定职责，对本法 律意见书出具日以前已经发生或者存在的事实进行了充分的核查验证，保证本法 律意见书所认定的事实真实、准确 ...